2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P1866A
    β-Endorphin, equine TFA
    β-Endorphin, equine TFA is an endogenous opioid peptide, which binds at high affinity to both μ/δ opioid receptors. β-Endorphin, equine TFA has analgesic properties.
    β-Endorphin, equine TFA
  • HY-P2932A
    Cholecystokinin-33 free acid
    Cholecystokinin-33 free acid is an analogue of Cholecystokinin (HY-P2932). C-terminal amidation is important for binding of Cholecystokinin to its receptors, and removing the amide group would decrease Cholecystokinin activity. Cholecystokinin-33 free acid can be used to study C-terminal amidation of Cholecystokinin-33.
    Cholecystokinin-33 free acid
  • HY-P3811A
    Autocamtide-3 acetate 99.62%
    Autocamtide-3 acetate, a 13-amino-acid peptide containing Thr287, is a selective CaMKII (Ca2+/calmodulin-dependent kinase II) (CaMK) substrate.
    Autocamtide-3 acetate
  • HY-P4106A
    Tat-GluR23Y, scrambled TFA 99.47%
    Tat-GluR23Y, scrambled TFA is the scrambled peptide of Tat-GluR23Y (HY-P2259). Tat-GluR23Y is a synthetic peptide containing tyrosine residues that inhibit AMPAR endocytosis and is effective in the research of long-term depression (LTD).
    Tat-GluR23Y, scrambled TFA
  • HY-P5154A
    Tamapin TFA 98.79%
    Tamapin TFA is a venom peptide, targeting to small conductance Ca(2+)-activated K(+) (SK) channels. Tamapin TFA is a selctive blocker of SK2 (Potassium Channel). Tamapin TFA inhibits SK channel-mediated currents in pyramidal neurons of the hippocampus. Tamapin TFA can be isolated from the Indian red scorpion (Mesobuthus tamulus).
    Tamapin TFA
  • HY-P5754B
    TAT-NEP1-40 acetate
    TAT-NEP1-40 acetate is a therapeutic candidate for axonal regeneration and functional recovery after stroke. TAT-NEP1-40 acetate can protect PC12 cells against oxygen and glucose deprivation (OGD) and promote neurite outgrowth. TAT-NEP1-40 acetate protects the brain against ischemia/reperfusion injury through inhibition of neuronal apoptosis. TAT-NEP1-40 acetate can be efficiently delivered into the rat brains.
    TAT-NEP1-40 acetate
  • HY-P5925A
    Ssm spooky toxin TFA
    Ssm Spooky Toxin TFA is found in Scolopendra mutilans that potently inhibits KCNQ (voltage-gated potassium channel family 7) channels, with IC50s of 2.8 μM, 5.26 μM and 0.1-0.3 M for Kv7.4, Kv1.3, and Shal channel, respectivily. Ssm Spooky Toxin TFA inhibits cytokine generation by specifically acting on the KV1.3 channel in T cells. Ssm Spooky Toxin TFA plays an essential role in the centipede’s circulatory system .
    Ssm spooky toxin TFA
  • HY-P6306A
    CS-6253 TFA 98.53%
    CS-6253 TFA is an agonist of ABCA1. CS-6253 TFA can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 TFA also has certain neuroprotective effects and can clear Aβ from the brain. CS-6253 TFA can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease.
    CS-6253 TFA
  • HY-Y0123S
    DL-Tyrosine-13C9,15N 202407-26-9 ≥98.0%
    DL-Tyrosine-13C9,15N is the 13C- and 15N-labeled DL-Tyrosine. DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine).
    DL-Tyrosine-13C9,15N
  • HY-Y0304S
    Dibutyl phthalate-3,4,5,6-d4 93952-11-5 98.5%
    Dibutyl phthalate-3,4,5,6-d4 is the deuterium labeled Dibutyl phthalate. Dibutyl phthalate is a commonly used plasticizer commonly found in some food packaging materials, personal care products, and the coating of oral medications. May cause toxicity and adverse neurobehavioral effects.
    Dibutyl phthalate-3,4,5,6-d4
  • HY-100530B
    Sp-cAMPS 71774-13-5 98%
    Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS binds the PDE10 GAF domain with an EC50 of 40 μM.
    Sp-cAMPS
  • HY-100815C
    (RS)-AMPA hydrobromide 171259-81-7 99.50%
    (RS)-AMPA ((±)-AMPA) hydrobromide is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA hydrobromide does not interfere with binding sites for kainic acid or NMDA receptors.
    (RS)-AMPA hydrobromide
  • HY-101373A
    Zolantidine dimaleate 104076-39-3 99.88%
    Zolantidine dimaleate (SKF 95282 dimaleate) is a potent, selective and cross the blood-brain barrier histamine H2 antagonist. Zolantidine dimaleate induces antinociception.
    Zolantidine dimaleate
  • HY-103565A
    AMN082 free base 83027-13-8 98.37%
    AMN082 free base, a selective, orally active, and brain penetrant mGluR7 agonist, directly activates receptor signaling via an allosteric site in the transmembrane domain. AMN082 free base potently inhibits cAMP accumulation and stimulates GTPγS binding (EC50 values, 64-290 nM) at transfected mammalian cells expressing mGluR7. AMN082 free base shows selectivity over other mGluR subtypes and selected ionotropic glutamate receptors. Antidepressant effects.
    AMN082 free base
  • HY-104028A
    BAY 73-6691 racemate 794568-90-4 99.86%
    BAY 73-6691 racemate is a phosphodiesterase 9 inhibitor extracted from patent WO 2017070293 A1.
    BAY 73-6691 racemate
  • HY-105545A
    Levetimide 21888-99-3 99.96%
    Levetimide is a potent and stereoselective inhibitor of [3H](+)pentazocine binding, with a Ki of 2.2 nM.
    Levetimide
  • HY-106587A
    Octoclothepin maleate salt 4789-68-8 99.14%
    Octoclothepin maleate salt, an orally active neuroleptic agent, is a dual SR-2A and D2DR inhibitor. Octoclothepin maleate salt reveals an intensive central depressant action in a series of observational and instrumental procedures in rodents.
    Octoclothepin maleate salt
  • HY-107382A
    RF9 hydrochloride 99.91%
    RF9 hydrochloride is a potent and selective Neuropeptide FF receptor antagonist, with Ki values of 58 and 75 nM for hNPFF1R and hNPFF2R, respectively.
    RF9 hydrochloride
  • HY-107663A
    MIF-1 TFA 35240-69-8 99.25%
    MIF-1 TFA (Melanostatin), an endogenous brain peptide, is a potent dopamine receptor allosteric modulator. MIF-1 TFA inhibits melanin formation. MIF-1 TFA blocks the effects of opioid receptor activation to modulate the analgesic effects. MIF-1 TFA accesses from the blood to the CNS by directly crossing the blood-brain barrier (BBB).
    MIF-1 TFA
  • HY-108698A
    (R)-Preclamol hydrochloride 89874-80-6 ≥98.0%
    (R)-Preclamol hydrochloride ((+)-3-PPP hydrochloride) is the R-enantiomer of Preclamol hydrochloride. (R)-Preclamol hydrochloride is a DA agonist with autoreceptor as well as postsynaptic receptor stimulatory properties.
    (R)-Preclamol hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity